News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

The Leukemia & Lymphoma Society and Epizyme Announce Achievement of Pre-clinical Milestone in DOT1L Personalized Therapeutic Partnership


3/13/2012 7:26:38 AM

WHITE PLAINS, N.Y. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--The Leukemia & Lymphoma Society (LLS) and Epizyme announced today that they have achieved a pre-clinical milestone in their partnership to develop Epizyme’s DOT1L-targeted histone methyltransferase inhibitor (HMTi) for Mixed Lineage Leukemia (MLL), a devastating acute leukemia that affects both pediatric and adult patients. Including this milestone, Epizyme has received, to date, $2.6 million of a potential $7.5 million in funding under the partnership with LLS to support the DOT1L program through Phase 1. Epizyme is creating personalized therapeutics for patients with genetically-defined cancers, with a focus on small molecule inhibitors of histone methyltransferases, an important epigenetic target class.

Read at BioSpace.com

comments powered by Disqus
   
Lymphoma
Leukemia

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES